DICE Therapeutics (DICE) News Today → Look Who Fired the World’s Richest Man (From Banyan Hill Publishing) (Ad) Free DICE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 26, 2024 | finance.yahoo.comQ3 2024 Resmed Inc Earnings CallApril 3, 2024 | msn.comMinishoot' Adventures Hits Steam: A Bullet-Hell Bonanza with a Zelda TwistMarch 8, 2024 | seekingalpha.comVoyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver EasierFebruary 24, 2024 | msn.comStoke City player ratings vs Cardiff as Potters sink into relegation zoneJanuary 31, 2024 | es-us.finanzas.yahoo.comAbercrombie Announces Official Partnership With McLaren Racing, Features Race Car in Fifth Avenue StoreJanuary 30, 2024 | msn.com15 Best Acne Treatment Products For Teens in 2024January 3, 2024 | finance.yahoo.comStar Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial OfficerDecember 30, 2023 | msn.comAltamira Therapeutics stock rises after it regains compliance with NasdaqNovember 29, 2023 | msn.comCan a Big Pharma Ever Be Worth $1 Trillion?November 4, 2023 | uk.finance.yahoo.comQ3 2023 Eli Lilly and Co Earnings CallOctober 25, 2023 | investing.comEli Lilly to buy Dice Therapeutics for $2.4 billionOctober 12, 2023 | es-us.finanzas.yahoo.comImmetas Therapeutics and GC Biopharma Announce Research Collaboration to Discover and Develop mRNA Therapeutics to Treat Autoimmune DiseasesOctober 3, 2023 | proactiveinvestors.comPoint Biopharma shares storm ahead 84% after Eli Lily's $1.4bn bidSeptember 29, 2023 | msn.comIs Eli Lilly Stock A Buy Now That It Has Topped A Profit-Taking Zone?September 11, 2023 | markets.businessinsider.comWells Fargo Sticks to Their Hold Rating for Incyte (INCY)August 22, 2023 | marketbeat.comWhy These 3 Large Caps Are Bucking the August Slump (DICE)The three largest S&P 500 outperformers of August are tacking on gains in a weak market, making them intriguing momentum plays to watch for the rest of 2023.August 21, 2023 | marketbeat.comY Intercept Hong Kong Ltd Takes Position in DICE Therapeutics, Inc. (NASDAQ:DICE)Y Intercept Hong Kong Ltd bought a new position in shares of DICE Therapeutics, Inc. (NASDAQ:DICE - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 7,098 shares of the company's stock, valueAugust 9, 2023 | markets.businessinsider.comWhat 9 Analyst Ratings Have To Say About DICE TherapeuticsAugust 9, 2023 | finanznachrichten.deEli Lilly and Company: Lilly Completes Acquisition of DICE TherapeuticsAugust 9, 2023 | msn.comHC Wainwright & Co. Reiterates DICE Therapeutics (DICE) Neutral RecommendationAugust 9, 2023 | finance.yahoo.comLilly Completes Acquisition of DICE TherapeuticsAugust 9, 2023 | marketbeat.comVersor Investments LP Invests $286,000 in DICE Therapeutics, Inc. (NASDAQ:DICE)Versor Investments LP purchased a new position in DICE Therapeutics, Inc. (NASDAQ:DICE - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,000 shares of the company's stock, valued at approximatAugust 9, 2023 | marketbeat.comTrading was temporarily halted for "DICE" at 07:08 PM with a stated reason of "News pending."August 8, 2023 | finanznachrichten.deEli Lilly and Company: Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline AdvancementsAugust 8, 2023 | markets.businessinsider.comLilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline AdvancementsAugust 8, 2023 | marketbeat.comDICE Therapeutics, Inc. (NASDAQ:DICE) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC cut its stake in shares of DICE Therapeutics, Inc. (NASDAQ:DICE - Free Report) by 41.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,713 shares of the company's stock afterAugust 7, 2023 | marketbeat.comJump Financial LLC Has $496,000 Stock Holdings in DICE Therapeutics, Inc. (NASDAQ:DICE)Jump Financial LLC lessened its stake in shares of DICE Therapeutics, Inc. (NASDAQ:DICE - Free Report) by 41.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,311 shares of the company's stock afteJuly 25, 2023 | markets.businessinsider.comLilly Extends Tender Offer To Acquire DICEJuly 25, 2023 | finance.yahoo.comLilly Announces Extension of Tender Offer to Acquire DICEJuly 12, 2023 | msn.comDrugmakers’ deal making will plow ahead despite antitrust scrutiny, analysts sayJuly 6, 2023 | msn.comDICE Therapeutics (DICE) Price Target Decreased by 19.70% to 50.21June 27, 2023 | finance.yahoo.comMergers Are Down, but These 2 Sectors Are BoomingJune 26, 2023 | benzinga.comShort Volatility Alert: Dice TherapeuticsJune 26, 2023 | msn.comNeedham Downgrades DICE Therapeutics (DICE)June 26, 2023 | benzinga.comNeedham Downgrades DICE Therapeutics to HoldJune 23, 2023 | marketbeat.comNorthpond Ventures Gp, Llc Sells 2,492,871 Shares of DICE Therapeutics, Inc. (NASDAQ:DICE) StockDICE Therapeutics, Inc. (NASDAQ:DICE - Get Rating) major shareholder Northpond Ventures Gp, Llc sold 2,492,871 shares of the firm's stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $46.50, for a total value of $115,918,501.50. Following the completion of the sale, the insider now directly owns 166,293 shares in the company, valued at approximately $7,732,624.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.June 23, 2023 | marketbeat.comBrokers Issue Forecasts for DICE Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:DICE)DICE Therapeutics, Inc. (NASDAQ:DICE - Get Rating) - Stock analysts at HC Wainwright lowered their FY2027 earnings estimates for DICE Therapeutics in a report issued on Wednesday, June 21st. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($5.82) fJune 21, 2023 | markets.businessinsider.comDice Therapeutics (DICE) Receives a New Rating from a Top AnalystJune 21, 2023 | marketbeat.comRed Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover (DICE)The market’s initial positive reaction to the DICE Therapeutics news suggests Eli Lilly shares will continue to sizzle this summer.June 21, 2023 | msn.comCantor Fitzgerald Downgrades DICE Therapeutics (DICE)June 21, 2023 | msn.comCanaccord Genuity Downgrades DICE Therapeutics (DICE)June 20, 2023 | msn.comAnalyst Expectations for DICE Therapeutics's FutureJune 20, 2023 | wsj.comThe Lilly-Dice Biotech Buyout Deals Short Sellers Another BlowJune 20, 2023 | fool.comEli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to KnowJune 20, 2023 | markets.businessinsider.comWhy DICE Therapeutics Stock Is Soaring TuesdayJune 20, 2023 | finance.yahoo.comLilly Decides to Roll the Dice: My Plan for the Stock NowJune 20, 2023 | finance.yahoo.comPayPal-KKR deal, Alibaba shares fall, Eli Lilly-Dice Therapeutics deal: Trending tickersJune 20, 2023 | finance.yahoo.comDice Therapeutics Stock Catapults To Record High On $2.4 Billion Eli Lilly BuyoutJune 14, 2023 | marketbeat.com1,038,125 Shares in DICE Therapeutics, Inc. (NASDAQ:DICE) Acquired by Alkeon Capital Management LLCAlkeon Capital Management LLC purchased a new position in DICE Therapeutics, Inc. (NASDAQ:DICE - Get Rating) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,038,125 shares of the company's stock, vJune 13, 2023 | finance.yahoo.comDICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023 Get DICE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DICE and its competitors with MarketBeat's FREE daily newsletter. Email Address The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet. See how you can invest alongside him DICE Media Mentions By Week DICE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DICE News Sentiment▼0.000.55▲Average Medical News Sentiment DICE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DICE Articles This Week▼01▲DICE Articles Average Week Get DICE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DICE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AMN Healthcare Services News CG Oncology News Privia Health Group News Maravai LifeSciences News Guardant Health News STAAR Surgical News Dyne Therapeutics News Geron News Apogee Therapeutics News RxSight News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DICE) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressWATCH: The Truth About InflationBirch GoldThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DICE Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
